Shares of Regeneron Pharmaceuticals Inc. (REGN) were up 4.7% in premarket trading on Thursday, the day after the company said it had submitted a request for emergency authorization to the Food and Drug Administration for its experimental antibody treatment. The therapy was prescribed to President Donald Trump last week as part of his COVID-19 treatment plan; on Wednesday, in a video, Trump called it a "cure." ( ) (He was also prescribe ( Gilead Sciences Inc.'s (GILD) remdesivir and the steroid dexamethasone.) Regeneron's announcement to file for an emergency use authorization (EUA) came the same day that Eli Lilly & Co. (LLY), which is also developing an antibody treatment for mild to moderate COVID-19 patients, announced Wednesday morning it had requested an EUA ( ). Regeneron's stock is up 57.6% so far this year. The S&P 500 , in comparison, has gained 5.8%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
October 08, 2020 08:31 ET (12:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.